A Sarasota Memorial specialist helped create new guidelines for treating differentiated thyroid cancer. The "2025 American Thyroid Association Management Guidelines" are the first update since 2015.

July 4, 2008 — The experimental drug motesanib (under development by Amgen) has shown activity in progressive advanced thyroid cancer in a phase 2 trial in 93 patients. This is one of the largest ...

Thyroid cancer is the most common endocrine cancer, affecting more people each year as detection rates continue to rise.

There is no universally accepted definition for recurrence of differentiated thyroid cancer (DTC) across treatment categories such as total thyroidectomy with or without radioactive iodine ablation ...

Postoperative radioiodine (RAI) versus no radiodine therapy for patients with low-risk differentiated thyroid cancer: A systematic review and meta-analysis. Survival outcomes in radioactive ...

Two prospective trials of immunotherapy in thyroid cancer, one of them negative, provided support for precision-medicine approaches that include immunotherapy. The studies were reported simultaneously ...

The leading, peer-reviewed resource for original articles, patient-focused reports, and translational research on thyroid cancer and all thyroid related diseases. These revised guidelines begin with ...

Thyroid cancer is the most common endocrine cancer, affecting more people each year as detection rates continue to rise.

Recurrent IRTC invading the upper aerodigestive tract remains a formidable clinical challenge. Management typically involves tracheal resection or laryngectomy, often with sacrifice of the recurrent ...